Media Type: eBook
Availability: In stock
The field of gene therapy has hurtled to the forefront of medical research in recent years. Advancements in genetic sequencing, gene delivery technologies and proof-of-principle work in cell culture and animal disease models have resulted in human gene therapy trials across a wide range of genetic diseases.
While many medical disciplines are conducting ongoing investigations, ophthalmology, in particular the field of inherited retinal diseases, leads the way with the first published phase III clinical trial and United States Food and Drug Administration (US FDA)–approved gene therapy.
This Focal Points module summarizes ongoing gene therapy trials for ocular diseases in the US and reviews the unique advantages of intraocular gene therapy. The role of genetic testing and the importance of a multidisciplinary team, including the threshold for referring to an ophthalmic geneticist, is also discussed.
Complete this module to:
Authors: Joseph M. Simonett, MD; Mark E. Pennesi, MD, PhD
Focal Points issues review the most crucial advances and feature insights to help you integrate tested research into your practice.
Subscribers receive 12 issues a year, plus access to the Focal Points digital archive.
This issue includes an audio version.
To access the audio version of this module, scan the QR code in the print module or click the link within the digital module.
To access this issue from your laptop or desktop computer, log in to www.aao.org/myonlineproducts with your Academy username and password.
To access this issue from your smartphone or tablet, use the free AAO eBooks app.
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.